YDES YD Bio Ltd Annual reports only
Services-Medical Laboratories · Nasdaq · SEC CIK 2011674 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY16.9%
TTM net income YoY-488.8%
TTM EPS YoY-500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin28.1%
Operating margin-883.3%
Net margin-1,392.6%
FCF margin-1,346.6%
EBITDA margin-880.6%
Returns
ROE-445.1%
ROA-80.5%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets120.7%
Debt / equity—
Current ratio5.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue241.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $596,817 | $510,360 | $350,131 |
| Cost of revenue | $429,407 | $355,004 | $196,686 |
| Gross profit | $167,410 | $155,356 | $153,445 |
| R&D expense | $1.60M | $491,353 | — |
| SG&A expense | $3.66M | $1.12M | $153,069 |
| Operating income | -$5.27M | -$1.46M | -$9,847 |
| Interest expense | — | $772 | $2,144 |
| Pretax income | -$8.31M | -$1.39M | $17,650 |
| Income tax | -$1,531 | $25,080 | $4,090 |
| Net income | -$8.31M | -$1.41M | $13,560 |
| EBITDA | -$5.26M | -$1.45M | -$7,395 |
| EPS (basic) | -0.12 | -0.02 | 0.00 |
| EPS (diluted) | -0.12 | -0.02 | 0.00 |
| Weighted avg. shares (diluted) | 66.72M | 64.73M | 64.73M |
| Balance sheet | |||
| Cash & equivalents | $6.01M | $3.13M | $87,098 |
| Receivables | $167,477 | $86,582 | — |
| Inventory | $1.88M | $37,335 | — |
| Current assets | $9.67M | $3.47M | — |
| PP&E, net | $59,340 | $64,379 | — |
| Intangibles | $2.61M | $2.68M | — |
| Total assets | $13.78M | $6.86M | — |
| Current liabilities | $1.64M | $263,060 | — |
| Long-term debt | $6,764 | — | — |
| Total debt | $6,764 | — | — |
| Total liabilities | $16.64M | $273,980 | — |
| Shareholders' equity | -$2.86M | $6.59M | $22,994 |
| Net debt | -$6.00M | — | — |
| Shares outstanding | 70.79M | 64.73M | — |
| Cash flow statement | |||
| Operating cash flow | -$6.60M | -$1.22M | -$55,657 |
| Capital expenditure | $1.44M | $74,914 | $290 |
| Free cash flow | -$8.04M | -$1.30M | -$55,947 |
| Investing cash flow | -$1.44M | -$2.90M | -$290 |
| Financing cash flow | $10.87M | $7.11M | $113,887 |
| Depreciation & amortization | $16,246 | $10,199 | $2,452 |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.